|
|
|
|
|
|
|
07.08.25 - 22:03
|
Dynavax Reports Second Quarter 2025 Financial Results (PR Newswire)
|
|
|
Record HEPLISAV-B® quarterly net product revenue of $92 million, representing 31% year-over-year growth Refines full year 2025 HEPLISAV-B net product revenue guidance range to $315 to $325 million, from $305 to $325 million Top-line results in Part 1 of Phase 1/2 shingles vaccine trial......
|
|
|
|
|
23.06.25 - 14:06
|
Pharma & Vaccine Industry Leader Eddie Gray joins Botanical Solution Inc. (BSI) Board of Directors (Business Wire)
|
|
|
Former GlaxoSmithKline President (Europe), Dynavax CEO & UK Government Chair Covid-19 Taskforce to provide strategic guidance for Botanical Solution's future developmentDAVIS, Calif.--(BUSINESS WIRE)--Eddie Gray, veteran pharmaceutical and vaccine industry executive, has joined the Board of Directors of Botanical Solution Inc. (BSI). Mr. Gray is the former President of GlaxoSmithKline Europe, former CEO Dynavax Technologies Corp. and former Chair of the UK Government's Covid-19 Antivirals Task Force. Eddie earned his B.Sc. (Honors) in Chemistry and Management Studies from the University of London, and completed his MBA at the Cranfield School of Management, England.
Botanical Solution produces the Gold Standard vaccine adjuvant QS-21. Currently, QS-21 is a vital component in FDA-approved vaccines against Shingles, Respiratory Syncytial Virus (RSV), Covid-19 and Malaria. QS-21 is at present extracted from an exotic tree, the Quillaja saponaria, which grows in the country of Chile. Chilean deforestation l...
|
|
|
|
|
|
|
|
|
|
|
04.06.25 - 23:01
|
Dynavax Comments on Glass Lewis Recommendation (PR Newswire)
|
|
|
Dynavax is Already Delivering Significant Long Term Stockholder Value Through Execution of Current Strategy Overseen by Board; Deep Track's Inferior Short-Term Plan and Nominees are Not in the Best Interests of All Stockholders Glass Lewis' Recommendation Recognizes the Significant......
|
|
|
|
|
24.05.25 - 00:18
|
Deep Track Capital Comments on ISS Recommendation (Business Wire)
|
|
|
Strongly Disagrees with Recommendation and Believes ISS Ignored Key Issues in Its Incomplete Analysis
ISS Has Chosen Not to Hold the Board Accountable for Its Underperformance in Recent Years, Heplisav's Waning Market Share Growth and Poor Corporate Governance
Urges Shareholders to Vote FOR Deep Track's Four Highly Qualified Director Nominees
GREENWICH, Conn.--(BUSINESS WIRE)--Deep Track Capital, LP, (together with its affiliates, “Deep Track” or “we”), one of the largest shareholders of Dynavax Technologies Corporation (NASDAQ: DVAX) (“Dynavax”, “DVAX” or the “Company”), with ownership of approximately 14.82% of the Company's outstanding shares, today issued the following statement in response to a report issued by Institutional Shareholder Services Inc. (“ISS”) regarding the election of directors to the Company's Board of Directors (the “Board”) at the 2025 Annual Meeting of Stockholders (the “Annual Meeting”).
“We firmly believe ISS reached the wrong conclusion by ...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
